Nefrena Tablet
Product Overview
Key Features
I -Ketoanalogue Tablets
a cCalcium-3-methyl-2-oxo-valerate 67 mg
(I -ketoanalogue to isoleucine , calcium salt)
a cCalcium-4-methyl-2-oxo-valerate 101 mg
(I -ketoanalogue to leucine , calcium salt)
a cCalcium-2-oxo-3-phenylpropionate 68 mg
(I -ketoanalogue to phenylalanine , calcium salt)
a cCalcium-3-methyl-2-oxo-butyrate 86 mg
(I -ketoanalogue to valine , calcium salt)
a cCalcium-dl-2-hydroxy-4(methylthio) butyrate 59 mg
(I -hydroxyanalogue to methionine , calcium salt)
a cLysine acetate 105 mg (Eq to lysine 75 mg.)
a cL-threonine 53 mg
a cL-tryptophan 23 mg
a cL-histidine 38 mg
a cL-tyrosine 30 mg
a cTotal nitrogen content per tablet 36 mg
a cCalcium content per tablet 1.25 mmol=0.05 gm
Dietary protein restriction may improve determinants of CKD progression. However, the extent of improvement and effect of ketoanalogue supplementation are unclear. We conducted a prospective, randomized, controlled trial of safety and efficacy of ketoanaloguea supplemented vegetarian very lowa protein diet (KD) compared with conventional lowa protein diet (LPD). Primary end point was RRT initiation or >50% reduction in initial eGFR. Nondiabetic adults with stable eGFR<30 ml/min per 1.73 m2, proteinuria <1 g/g urinary creatinine, good nutritional status, and good diet compliance entered a run-in phase on LPD. After 3 months, compliant patients were randomized to KD (0.3 g/kg vegetable proteins and 1 cps/5 kg ketoanalogues per day) or continue LPD (0.6 g/kg per day) for 15 months. Only 14% of screened patients patients were randomized, with no differences between groups. Adjusted numbers needed to treat (NNTs; 95% confidence interval) to avoid composite primary end point in intention to treat and per-protocol analyses in one patient were 4.4 (4.2 to 5.1) and 4.0 (3.9 to 4.4), respectively, for patients with eGFR<30 ml/min per 1.73 m2. Adjusted NNT (95% confidence interval) to avoid dialysis was 22.4 (21.5 to 25.1) for patients with eGFR<30 ml/min per 1.73 m2 but decreased to 2.7 (2.6 to 3.1) for patients with eGFR<20 ml/min per 1.73 m2 in intention to treat analysis. Correction of metabolic abnormalities occurred only with KD. Compliance to diet was good, with no changes in nutritional parameters and no adverse reactions. Thus, this KD seems nutritionally safe and could defer dialysis initiation in some patients with CKD - Journal of the American Society of Nephrology.
Company Details
Business Type
Supplier, Trading Company
Employee Count
30
Establishment
2003
Working Days
Monday To Sunday
GST NO
07AAECA9312Q1ZA
Seller Details
AAR ESS REMEDIES PVT. LTD.
GST
07AAECA9312Q1ZA
DIRECTOR
Mr Sandeep Sharma
Member Since
8 Years
AddressView on Map
Wz 13e, Lane No.4, Vashisth Park, Pankha Road, New Delhi, Delhi, 110046, India
Report incorrect details
Related Products
Alpha Ketoanalogue Tablets Specific Drug
Price - 300 INR (Approx.)
MOQ - 1 Box/Boxes
RADHEY HEALTHCARE
New Delhi, Delhi
Alpha Ketoanalogue Tablets For Chronic Kidney Disease Application: Industrial
Price - 290 INR (Approx.)
MOQ - 200 Box/Boxes
MEDPRO DISTRIBUTORS
New Delhi, Delhi
Alpha Ketoanalogue Tablet
Price - 40 INR (Approx.)
MOQ - 20 Box/Boxes
XENON PHARMA PVT LTD
New Delhi, Delhi
Nephrokit Alpha Ketoanalogue Tablet Purity: 98%
Price - 800 INR (Approx.)
MOQ - 20 Box/Boxes
Nephro Star Healthcare Pvt Ltd
New Delhi, Delhi
Alpha Ketoanalogue Tablets Aplazar General Medicines
Price - 107 INR (Approx.)
MOQ - 1 Piece/Pieces
AV PHARMA
Delhi, Delhi
Alpha Ketoanalogue Tablets Specific Drug
Price - 300 INR (Approx.)
MOQ - 1 Box/Boxes
RADHEY HEALTHCARE
New Delhi, Delhi
More Products From This Seller
Recommended Products
Explore Related Categories
- Tradeindia
- Cardiovascular Drugs
- Alpha Ketoanalogue Tablet
- Nefrena Tablet In Pankha Road